Mehmet Eltan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mehmet Eltan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Serap Turan
Marmara University School of Medicine Department of Pediatric Endocrinology, Istanbul, Turkey
3 shared publications - Tulay Guran
Department of Pediatric Endocrinology and Diabetes, Faculty of Medicine, Marmara University , 34854, Istanbul
3 shared publications - Zehra Yavas Abali
Pediatric Endocrinology and Diabetes, Department of Pediatrics School of Medicine Marmara University Istanbul Turkey
3 shared publications - Abdullah Bereket
Department of Pediatric Endocrinology, Marmara University Faculty of Medicine, İstanbul, Türkiye
2 shared publications - Ahmet Arman
Marmara University
2 shared publications - Ceren Alavanda
Department of Medical Genetics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye
2 shared publications
Latest Publications
- 7 November 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
Isolated Hyperchlorhidrosis Caused by Novel Biallelic CA12 Variants Mimicking Pseudohypoaldosteronism
Background: Isolated hyperchlorhidrosis (HYCHL; OMIM 143860) is caused by biallelic CA12 variants encoding carbonic anhydrase XII (CA XII), a transmembrane enzyme that mediates sodium and chloride reabsorption in sweat glands, leading to excessive salt loss. Clinically, HYCHL presents in infancy with recurrent hyponatremic dehydration secondary to excessive salt loss, often mimicking pseudohypoaldosteronism (PHA) or cystic fibrosis (CF). Case Presentation: A 5-month-old girl presented with irritability, lethargy, poor feeding, severe hyponatremia (110 mEq/L), and hyperkalemia (7.1 mEq/L). Congenital adrenal hyperplasia was excluded by endocrine evaluation. Markedly elevated plasma renin activity and aldosterone initially suggested PHA; however, low urinary sodium excretion during hyponatremia indicated an extrarenal source of salt loss. Three further episodes occurred, predominantly during summer. Although the parents consistently reported a salty taste of the infant’s skin. Clinical exome sequencing identified two unreported compound heterozygous CA12 missense variants, c.823C>T p.(Arg275Trp) and c.694C>A p.(Pro232Thr), with parental testing confirming trans inheritance. No pathogenic variants were detected in CFTR or PHA-associated genes. By 19 months of age, the patient had remained free of hyponatremic episodes for nine months without disease-specific treatment, with normal growth and neurodevelopment. Conclusion: This case expands the mutational spectrum of isolated hyperchlorhidrosis by identifying two unreported variants in CA12 and highlights the importance of considering isolated hyperchlorhidrosis in infants with recurrent salt-wasting when routine evaluation does not support PHA or CF.
- 7 November 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
Isolated Hyperchlorhidrosis Caused by Novel Biallelic CA12 Variants Mimicking Pseudohypoaldosteronism
Background: Isolated hyperchlorhidrosis (HYCHL; OMIM 143860) is caused by biallelic CA12 variants encoding carbonic anhydrase XII (CA XII), a transmembrane enzyme that mediates sodium and chloride reabsorption in sweat glands, leading to excessive salt loss. Clinically, HYCHL presents in infancy with recurrent hyponatremic dehydration secondary to excessive salt loss, often mimicking pseudohypoaldosteronism (PHA) or cystic fibrosis (CF). Case Presentation: A 5-month-old girl presented with irritability, lethargy, poor feeding, severe hyponatremia (110 mEq/L), and hyperkalemia (7.1 mEq/L). Congenital adrenal hyperplasia was excluded by endocrine evaluation. Markedly elevated plasma renin activity and aldosterone initially suggested PHA; however, low urinary sodium excretion during hyponatremia indicated an extrarenal source of salt loss. Three further episodes occurred, predominantly during summer. Although the parents consistently reported a salty taste of the infant’s skin. Clinical exome sequencing identified two unreported compound heterozygous CA12 missense variants, c.823C>T p.(Arg275Trp) and c.694C>A p.(Pro232Thr), with parental testing confirming trans inheritance. No pathogenic variants were detected in CFTR or PHA-associated genes. By 19 months of age, the patient had remained free of hyponatremic episodes for nine months without disease-specific treatment, with normal growth and neurodevelopment. Conclusion: This case expands the mutational spectrum of isolated hyperchlorhidrosis by identifying two unreported variants in CA12 and highlights the importance of considering isolated hyperchlorhidrosis in infants with recurrent salt-wasting when routine evaluation does not support PHA or CF.
- 30 June 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-15
Functional impact of a novel intronic TG variant in congenital goiter and thyroid dyshormonogenesis
Introduction: Thyroglobulin (TG) is essential for the biosynthesis of thyroid hormones. Biallelic pathogenic variants in the TG gene cause primary congenital hypothyroidism due to dyshormonogenesis (DHG), which often presents with congenital goiter. Here, we report a novel homozygous intronic TG variant, identified in a family with multiple cases of congenital goiter, and demonstrate its pathogenicity using cDNA sequencing. Case presentation: The proband, a 15.5-year-old male, presented with a thyroid nodule and had a history of congenital goiter. He had been treated with levothyroxine since birth. Serum TG concentration was markedly low. Thyroid ultrasound revealed diffuse heterogeneity and a solid nodule. Thyroidectomy was performed due to atypia of undetermined significance on fine-needle aspiration biopsy, and histopathological examination revealed adenomatoid hyperplasia. Analysis of the proband revealed a novel homozygous c.5686+3A>C variant in TG (NM_003235). In silico analysis predicted a splice-altering variant, and the variant was absent from gnomAD. Analysis of cDNA sequencing confirmed that this variant causes exon 30 skipping, leading to an in-frame deletion and presumably a nonfunctional TG protein. In a subsequent pregnancy evaluated during the course of this case, fetal goiter was identified and treated with intra-amniotic levothyroxine. Conclusion: This study reports a novel intronic TG variant causing aberrant splicing, thereby expanding the molecular spectrum of primary congenital hypothyroidism and emphasizing the importance of early genetic diagnosis for effective counseling and prevention of recurrence.
- 30 June 2026
- Published by S. Karger AG in Hormone Research in Paediatrics
- p. 1-15
Functional impact of a novel intronic TG variant in congenital goiter and thyroid dyshormonogenesis
Introduction: Thyroglobulin (TG) is essential for the biosynthesis of thyroid hormones. Biallelic pathogenic variants in the TG gene cause primary congenital hypothyroidism due to dyshormonogenesis (DHG), which often presents with congenital goiter. Here, we report a novel homozygous intronic TG variant, identified in a family with multiple cases of congenital goiter, and demonstrate its pathogenicity using cDNA sequencing. Case presentation: The proband, a 15.5-year-old male, presented with a thyroid nodule and had a history of congenital goiter. He had been treated with levothyroxine since birth. Serum TG concentration was markedly low. Thyroid ultrasound revealed diffuse heterogeneity and a solid nodule. Thyroidectomy was performed due to atypia of undetermined significance on fine-needle aspiration biopsy, and histopathological examination revealed adenomatoid hyperplasia. Analysis of the proband revealed a novel homozygous c.5686+3A>C variant in TG (NM_003235). In silico analysis predicted a splice-altering variant, and the variant was absent from gnomAD. Analysis of cDNA sequencing confirmed that this variant causes exon 30 skipping, leading to an in-frame deletion and presumably a nonfunctional TG protein. In a subsequent pregnancy evaluated during the course of this case, fetal goiter was identified and treated with intra-amniotic levothyroxine. Conclusion: This study reports a novel intronic TG variant causing aberrant splicing, thereby expanding the molecular spectrum of primary congenital hypothyroidism and emphasizing the importance of early genetic diagnosis for effective counseling and prevention of recurrence.
- 9 March 2026
- Published by Wiley in Clinical Endocrinology
Diagnostic Utility of Genetic Testing in Hyperthyroxinemia With Non‐Suppressed TSH
Background: Hyperthyroxinemia with non‐suppressed thyroid‐stimulating hormone (TSH) is a complex clinical entity that presents significant diagnostic challenges. Inherited causes include resistance to thyroid hormone beta (RTHβ), characterised by highly variable clinical presentation, and familial dysalbuminemic hyperthyroxinemia (FDH), a form of assay interference caused by pathogenic variants in the ALB gene leading to pseudo elevation of free thyroxine (FT4). This study aimed to characterise the clinical, laboratory, and molecular features of a paediatric cohort presenting with hyperthyroxinemia and non‐suppressed TSH, and to identify clinical parameters that may aid in differential diagnosis. Methods: In this retrospective observational study, 25 children from 19 unrelated families with elevated FT4 and non‐suppressed TSH were evaluated. Clinical history, anthropometric data, physical examination findings, vital signs, laboratory results, radiological imaging, and sequencing data of the THRB and/or ALB genes were reviewed. Results: THRB gene sequencing was performed in 21 children from 18 families, identifying pathogenic or likely pathogenic variants in six patients from six unrelated families, including a novel variant c.997 G > C, p.(Glu333Gln), consistent with a diagnosis of RTHβ in 33.3% of those tested. Among these patients, tachycardia was observed in three cases (50%). ALB gene sequencing was completed in 16 children from 13 families, revealing the hotspot variant c.725 G > A, p.(Arg242His) in 12 patients from six unrelated families, corresponding to FDH in 46.2% of those tested. None of the FDH‐confirmed patients exhibited tachycardia or other signs of thyroid dysfunction. FT4 and TSH levels were similar between RTHβ and FDH groups; however, FT3 levels tended to be lower in FDH, although FT3/FT4 ratio did not differ significantly. Conclusion: Our findings highlight the critical role of molecular testing in accurately diagnosing the underlying cause of elevated FT4 with non‐suppressed TSH and in preventing unnecessary interventions. Hotspot analysis of the ALB gene is recommended as a first‐line test, particularly in asymptomatic individuals.
- 9 March 2026
- Published by Wiley in Clinical Endocrinology
Diagnostic Utility of Genetic Testing in Hyperthyroxinemia With Non‐Suppressed TSH
Background: Hyperthyroxinemia with non‐suppressed thyroid‐stimulating hormone (TSH) is a complex clinical entity that presents significant diagnostic challenges. Inherited causes include resistance to thyroid hormone beta (RTHβ), characterised by highly variable clinical presentation, and familial dysalbuminemic hyperthyroxinemia (FDH), a form of assay interference caused by pathogenic variants in the ALB gene leading to pseudo elevation of free thyroxine (FT4). This study aimed to characterise the clinical, laboratory, and molecular features of a paediatric cohort presenting with hyperthyroxinemia and non‐suppressed TSH, and to identify clinical parameters that may aid in differential diagnosis. Methods: In this retrospective observational study, 25 children from 19 unrelated families with elevated FT4 and non‐suppressed TSH were evaluated. Clinical history, anthropometric data, physical examination findings, vital signs, laboratory results, radiological imaging, and sequencing data of the THRB and/or ALB genes were reviewed. Results: THRB gene sequencing was performed in 21 children from 18 families, identifying pathogenic or likely pathogenic variants in six patients from six unrelated families, including a novel variant c.997 G > C, p.(Glu333Gln), consistent with a diagnosis of RTHβ in 33.3% of those tested. Among these patients, tachycardia was observed in three cases (50%). ALB gene sequencing was completed in 16 children from 13 families, revealing the hotspot variant c.725 G > A, p.(Arg242His) in 12 patients from six unrelated families, corresponding to FDH in 46.2% of those tested. None of the FDH‐confirmed patients exhibited tachycardia or other signs of thyroid dysfunction. FT4 and TSH levels were similar between RTHβ and FDH groups; however, FT3 levels tended to be lower in FDH, although FT3/FT4 ratio did not differ significantly. Conclusion: Our findings highlight the critical role of molecular testing in accurately diagnosing the underlying cause of elevated FT4 with non‐suppressed TSH and in preventing unnecessary interventions. Hotspot analysis of the ALB gene is recommended as a first‐line test, particularly in asymptomatic individuals.
- 4 February 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , 225-232
Adrenal androgens as predictors of growth characteristics in premature pubarche
Background: Premature pubarche (PP) is characterized by the early onset of pubic or axillary hair, body odor, or mild acne, most commonly reflected by elevated plasma dehydroepiandrosterone-sulfate (DHEA-S) concentrations. However, recent evidence suggests that 11-oxygenated adrenal androgens [11β-hydroxyandrostenedione (11OHA4), 11β-hydroxytestosterone (11OHT)] may better represent true androgenic activity. Aim: This study aims to evaluate the predictive value of adrenal androgens in determining growth characteristics among girls with PP. Subjects and Methods: A prospective study was conducted to evaluate anthropometric and clinical features and to quantify plasma adrenal androgens—including DHEA, DHEA-S, androstenedione (A4), androsterone, 11OHA4, and 11OHT—using liquid chromatography-mass spectrometry in 53 girls with isolated PP at presentation and during follow-up. Thirty-six age-matched girls without PP served as the control group. Results: The height, body mass index-standard deviation score (SDS), DHEA, DHEA-S, A4, androsterone, and 17OH-pregnenolone concentrations were higher (P < .0001), whereas no difference in 11OHA4 and 11OHT concentrations was observed in the PP group compared with controls. There was no correlation of adrenal androgen concentrations with height, corrected height, and growth velocity at baseline or during follow-up of 2.7 years. Corrected height SDS was positively correlated with baseline corrected height SDS (r = .63, P < .0001), baseline bone age (BA)/chronological age ratio (r = .31, P = .02), and baseline BA SDS (r = .32, P = .01) but not with hormone concentrations. Conclusion: Isolated idiopathic PP appears to be a benign variant of normal development. In this setting, adrenal androgen concentrations are not associated with adverse linear growth outcomes and are unlikely to influence clinical management, supporting a conservative approach after exclusion of pathological causes.
- 4 February 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (2) , 225-232
Adrenal androgens as predictors of growth characteristics in premature pubarche
Background: Premature pubarche (PP) is characterized by the early onset of pubic or axillary hair, body odor, or mild acne, most commonly reflected by elevated plasma dehydroepiandrosterone-sulfate (DHEA-S) concentrations. However, recent evidence suggests that 11-oxygenated adrenal androgens [11β-hydroxyandrostenedione (11OHA4), 11β-hydroxytestosterone (11OHT)] may better represent true androgenic activity. Aim: This study aims to evaluate the predictive value of adrenal androgens in determining growth characteristics among girls with PP. Subjects and Methods: A prospective study was conducted to evaluate anthropometric and clinical features and to quantify plasma adrenal androgens—including DHEA, DHEA-S, androstenedione (A4), androsterone, 11OHA4, and 11OHT—using liquid chromatography-mass spectrometry in 53 girls with isolated PP at presentation and during follow-up. Thirty-six age-matched girls without PP served as the control group. Results: The height, body mass index-standard deviation score (SDS), DHEA, DHEA-S, A4, androsterone, and 17OH-pregnenolone concentrations were higher (P < .0001), whereas no difference in 11OHA4 and 11OHT concentrations was observed in the PP group compared with controls. There was no correlation of adrenal androgen concentrations with height, corrected height, and growth velocity at baseline or during follow-up of 2.7 years. Corrected height SDS was positively correlated with baseline corrected height SDS (r = .63, P < .0001), baseline bone age (BA)/chronological age ratio (r = .31, P = .02), and baseline BA SDS (r = .32, P = .01) but not with hormone concentrations. Conclusion: Isolated idiopathic PP appears to be a benign variant of normal development. In this setting, adrenal androgen concentrations are not associated with adverse linear growth outcomes and are unlikely to influence clinical management, supporting a conservative approach after exclusion of pathological causes.
- Open Access
- 16 January 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 10
Targeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series
Pathogenic variants in the SLC34A1 gene, which encodes the sodium-phosphate cotransporter NaPi-IIa, lead to a spectrum of renal tubular disorders, including infantile hypercalcemia type 2, nephrolithiasis/osteoporosis-hypophosphatemia type 2, and Fanconi renotubular syndrome type 2. Despite increasing recognition of SLC34A1 -related disorders, data on genotype–phenotype correlations and treatment response remain limited due to the rarity of the condition. We retrospectively analyzed the clinical, biochemical, and molecular features of 11 patients from unrelated families carrying 12 pathogenic or likely pathogenic SLC34A1 variants, three of which were novel. Next-generation sequencing and ACMG-AMP criteria were used for variant classification. Biochemical parameters including serum phosphate, calcium, parathyroid hormone, urinary calcium, and TmP/GFR were evaluated. Treatment response to oral phosphate supplementation was longitudinally assessed. All patients exhibited hypercalciuria and nephrocalcinosis at diagnosis. Oral phosphate supplementation (5–20 mg/kg/day) resulted in normalization of urinary calcium excretion in 10 of 11 cases, regardless of baseline serum phosphate status. Linear growth improved in all but one patient. The identified mutations clustered primarily within functional domains of the NaPi-IIa protein, particularly amino acid residues 109–205 and 375–487. Several splice-site and codon-specific variants—such as those affecting Gly153 and Gly194—were highlighted as potential pathogenic hotspots. Our findings expand the mutational and phenotypic spectrum of SLC34A1 -related disease and reinforce the utility of oral phosphate supplementation in managing hypercalciuria and promoting growth. Functional domain mapping and variant clustering analyses enhance understanding of disease mechanisms and support the importance of early diagnosis and long-term surveillance.
- 16 January 2026
- Published by Springer Nature in Calcified Tissue International
- Vol. 117 (1) , 10
Open AccessTargeting Hypercalciuria in SLC34A1-Related Disorders: Impact of Oral Phosphate Therapy and Novel Genetic Insights in Pediatric Case Series
Pathogenic variants in the SLC34A1 gene, which encodes the sodium-phosphate cotransporter NaPi-IIa, lead to a spectrum of renal tubular disorders, including infantile hypercalcemia type 2, nephrolithiasis/osteoporosis-hypophosphatemia type 2, and Fanconi renotubular syndrome type 2. Despite increasing recognition of SLC34A1 -related disorders, data on genotype–phenotype correlations and treatment response remain limited due to the rarity of the condition. We retrospectively analyzed the clinical, biochemical, and molecular features of 11 patients from unrelated families carrying 12 pathogenic or likely pathogenic SLC34A1 variants, three of which were novel. Next-generation sequencing and ACMG-AMP criteria were used for variant classification. Biochemical parameters including serum phosphate, calcium, parathyroid hormone, urinary calcium, and TmP/GFR were evaluated. Treatment response to oral phosphate supplementation was longitudinally assessed. All patients exhibited hypercalciuria and nephrocalcinosis at diagnosis. Oral phosphate supplementation (5–20 mg/kg/day) resulted in normalization of urinary calcium excretion in 10 of 11 cases, regardless of baseline serum phosphate status. Linear growth improved in all but one patient. The identified mutations clustered primarily within functional domains of the NaPi-IIa protein, particularly amino acid residues 109–205 and 375–487. Several splice-site and codon-specific variants—such as those affecting Gly153 and Gly194—were highlighted as potential pathogenic hotspots. Our findings expand the mutational and phenotypic spectrum of SLC34A1 -related disease and reinforce the utility of oral phosphate supplementation in managing hypercalciuria and promoting growth. Functional domain mapping and variant clustering analyses enhance understanding of disease mechanisms and support the importance of early diagnosis and long-term surveillance.
- 19 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e3021-e3030
Clinical and Molecular Genetic Characteristics of Patients with Hereditary Hypophosphatemia
Context: Hereditary hypophosphatemia (HH), is a rare condition related to decreased renal tubular phosphate reabsorption. Although X-linked hypophosphatemia or PHEX gene variant is the most frequent cause of HH, recent advances in next-generation sequencing (NGS) techniques enable the identification of genetic etiologies as a whole. Objective: This work aimed to identify genetic causes of HH using various genetic testing methods and to compare clinical features between FGF23-dependent and FGF23-independent HH groups. Methods: Fifty patients (24 males) from 39 unrelated families were included. Based on initial evaluation, PHEX gene sequencing was performed in patients with clinical and biochemical findings suggestive of FGF23-dependent HH. If sequencing showed no alterations, multiplex ligation-dependent probe amplification (MLPA) analysis for PHEX was conducted. Initially, a specific gene panel was performed for FGF23-independent HH or those in whom the PHEX gene showed no genetic alteration. Results: Genetic etiology was revealed in 43 patients from 33 families. PHEX gene variants (4 novel) were identified in 24 patients from 19 unrelated families (50%). SLC34A3 was the second most common (16.6%) and the rest were rarer causes of hypophosphatemia (DMP1 n = 3, SLC34A1 n = 2, CLCN5 n = 2, OCRL n = 2, FAM20C n = 1, SLC2A2 n = 1). When the genetically proven FGF23-dependent (n = 28) and FGF23-independent (n = 15) HH groups were compared for clinical and biochemical features; lower phosphate and TmP/GFR SDSs and higher ALP SDS with more severe clinical rickets were detected in FGF23-dependent group, whereas higher serum and urine calcium and lower PTH levels were detected in FGF23-independent group. Conclusion: The application of MLPA provided an additional explanatory value of 10% to the molecular etiology. However, 10% of the cases of HH still remain unexplained even after a comprehensive genetic work-up. Biochemical findings suggest distinct biochemical profiles between FGF23-dependent and FGF23-independent HH groups.
- 19 December 2024
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (9) , e3021-e3030
Clinical and Molecular Genetic Characteristics of Patients with Hereditary Hypophosphatemia
Context: Hereditary hypophosphatemia (HH), is a rare condition related to decreased renal tubular phosphate reabsorption. Although X-linked hypophosphatemia or PHEX gene variant is the most frequent cause of HH, recent advances in next-generation sequencing (NGS) techniques enable the identification of genetic etiologies as a whole. Objective: This work aimed to identify genetic causes of HH using various genetic testing methods and to compare clinical features between FGF23-dependent and FGF23-independent HH groups. Methods: Fifty patients (24 males) from 39 unrelated families were included. Based on initial evaluation, PHEX gene sequencing was performed in patients with clinical and biochemical findings suggestive of FGF23-dependent HH. If sequencing showed no alterations, multiplex ligation-dependent probe amplification (MLPA) analysis for PHEX was conducted. Initially, a specific gene panel was performed for FGF23-independent HH or those in whom the PHEX gene showed no genetic alteration. Results: Genetic etiology was revealed in 43 patients from 33 families. PHEX gene variants (4 novel) were identified in 24 patients from 19 unrelated families (50%). SLC34A3 was the second most common (16.6%) and the rest were rarer causes of hypophosphatemia (DMP1 n = 3, SLC34A1 n = 2, CLCN5 n = 2, OCRL n = 2, FAM20C n = 1, SLC2A2 n = 1). When the genetically proven FGF23-dependent (n = 28) and FGF23-independent (n = 15) HH groups were compared for clinical and biochemical features; lower phosphate and TmP/GFR SDSs and higher ALP SDS with more severe clinical rickets were detected in FGF23-dependent group, whereas higher serum and urine calcium and lower PTH levels were detected in FGF23-independent group. Conclusion: The application of MLPA provided an additional explanatory value of 10% to the molecular etiology. However, 10% of the cases of HH still remain unexplained even after a comprehensive genetic work-up. Biochemical findings suggest distinct biochemical profiles between FGF23-dependent and FGF23-independent HH groups.
- Open Access
- 8 August 2024
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (2) , 126-135
Expanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings
Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.
- 8 August 2024
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 17 (2) , 126-135
Open AccessExpanding the Clinical Features of Schimke Immuno-Osseous Dysplasia: A New Patient with a Novel Variant and Novel Clinical Findings
Schimke Immuno-Osseous Dysplasia (SIOD) (MIM:242900) is an ultra-rare autosomal recessive pan-ethnic pleiotropic disease. Typical findings of this syndrome are steroid-resistant nephrotic syndrome, cellular immunodeficiency and spondyloepiphyseal dysplasia and facial dysmorphism. Biallelic variants in the SMARCAL1 gene cause SIOD. The five-and-half-year-old female patient was evaluated because of short stature, dysmorphism, hypercalcemia, hypophosphatemia and elevated FSH levels. Karyotype analysis and array-CGH testing were normal. Clinical Exome Sequencing was performed via next-generation sequencing to analyze genes associated with hypophosphatemia. No pathogenic variant was detected. The subsequent detection of proteinuria during her follow-up for cross-fused ectopic left kidney ultimately facilitated the diagnosis of SIOD, although no obvious spondyloepiphyseal dysplasia was detected. Re-analysis of CES revealed a novel homozygous c.2422_2427+9delinsA pathogenic variant in the SMARCAL1. One hundred twenty-five SIOD cases from 38 literature reporting SMARCAL1 gene pathogenic variants were reviewed to investigate whether hypercalcemia, hypophosphatemia and elevated FSH levels had been previously reported in SIOD patients. This review revealed that this was the first time these findings had been reported in a SIOD patient. This report expands not only the phenotypic but also genotypic spectrum of SIOD.
- 15 December 2022
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 3 (4) , 163-169
Late-effects of Chemoradiotherapy on Growth and Puberty in Survivors of Childhood Acute Lymphoblastic Leukemia
- 15 December 2022
- Published by Aydin Pediatric Society in Trends in Pediatrics
- Vol. 3 (4) , 163-169
Late-effects of Chemoradiotherapy on Growth and Puberty in Survivors of Childhood Acute Lymphoblastic Leukemia